- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02488577
Outcomes of TAMIS-Total Mesorectal Excision Versus Transanal Loco-regional Excision for T2 Low Rectal Cancer (TAMIS)
September 10, 2018 updated by: Osama Mohammad Ali ElDamshety
Outcomes Comparison of TAMIS-TME Versus Transanal Minimally Invasive Locoregional Resection for T2 Low Rectal Cancer: an Open Label Study
Cases with stage T2 N0 low rectal cancer will undergo either Transanal minimally invasive total mesorectal excision or transanal minimally invasive locoregional resection.
Study Overview
Status
Unknown
Conditions
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- T2 N0 low rectal cancer
Exclusion Criteria:
- patients unfit for laparoscopic resection
- Unwilling to share in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: TAMIS TME
T2 N0 Cases which undergo transanal minimally invasive total mesorectal excision.
|
|
Active Comparator: TAMIS-Local
T2 N0 Cases which will undergo transanal minimally invasive locoregional resection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall percent of postoperative complications.
Time Frame: 30 days
|
the over all percentage of Postoperative complications concerning Pelvis abscess, anastomosis disruption, bleeding, Fistula and continence function.
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hospital stay
Time Frame: 30 days
|
Number of Days starting from the admission till discharge
|
30 days
|
Recurrence.
Time Frame: 2 years
|
number of local and distant recurrence
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Sherif Kotb, M.D., PhD., Professor of surgical oncology Mansoura university
- Principal Investigator: Osama Eldamshety, PhD, surgical oncology Mansoura university
- Principal Investigator: Adel Fathi, M.D., surgical oncology Mansoura university
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2015
Primary Completion (Anticipated)
June 1, 2019
Study Completion (Anticipated)
October 1, 2019
Study Registration Dates
First Submitted
June 30, 2015
First Submitted That Met QC Criteria
July 1, 2015
First Posted (Estimate)
July 2, 2015
Study Record Updates
Last Update Posted (Actual)
September 12, 2018
Last Update Submitted That Met QC Criteria
September 10, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MISS-TRICKR2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low Rectal Cancer
-
Sir Run Run Shaw HospitalRecruiting
-
Mansoura UniversityUnknown
-
Fujian Cancer HospitalNot yet recruiting
-
Fudan UniversityRecruitingEarly Low Rectal CancerChina
-
Jewish General HospitalUniversity of Manitoba; McGill University Health Centre/Research Institute... and other collaboratorsRecruitingLow Anterior Resection Syndrome | Rectal Cancer | Surgery | Patient Activation | Low Anterior ResectionCanada, United States
-
University of AarhusRecruitingLow Anterior Resection Syndrome | Rectal CancerDenmark
-
The First Hospital of Jilin UniversityNot yet recruitingFunctional Outcome | Diverting Ileostomy | Middle and Low Rectal Cancer | Stoma Complications
-
Fox Chase Cancer CenterCompletedRectal Cancer | Low Anterior ResectionUnited States
-
Medtronic - MITGUniversity of South Florida; Duke University; Providence Medical Research CenterTerminatedRectal Cancer | Low Anterior Resection | Proctosigmoid ResectionUnited States
-
KU LeuvenUniversitaire Ziekenhuizen KU LeuvenNot yet recruitingRectal Cancer | LARS - Low Anterior Resection Syndrome
Clinical Trials on Transanal minimally invasive total mesorectal excision
-
Mansoura UniversityUnknown
-
Sun Yat-sen UniversityCompleted
-
Third Military Medical UniversityCompletedRectal Cancer | Perioperative ComplicationChina
-
Yanhong DengCompleted
-
University Hospital Gregorio MarañónHospital del Río Hortega; Hospital de Leon; University of Navarrra Hospital (Clinica...RecruitingRectal Cancer | Sphincter Ani IncontinenceSpain
-
Ruijin HospitalWithdrawn
-
National Cancer Center, KoreaActive, not recruitingRectal CancerKorea, Republic of
-
Cantonal Hospital of St. GallenRecruitingRecurrence | Mortality | Survival | Postoperative MorbiditySwitzerland
-
National Cancer Center, KoreaCompletedRectal CancerKorea, Republic of
-
Icahn School of Medicine at Mount SinaiSociety of American Gastrointestinal and Endoscopic Surgeons; Research Foundation...Active, not recruiting